Academic Journals Database
Disseminating quality controlled scientific knowledge

The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial

Author(s): Park Kyungil | Chung Woo-Young | Seo Jae-Bin | Kim Sang-Hyun | Zo Joo-Hee | Kim Myung-A | Park Young-Bae

Journal: Trials
ISSN 1745-6215

Volume: 11;
Issue: 1;
Start page: 122;
Date: 2010;
Original page

Abstract Background Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clearly defined and debatable. Therefore additional prophylactic pretreatments are needed. Methods/Design The present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent. Discussion As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option. Trial registration NCT01165567
Save time & money - Smart Internet Solutions      Why do you need a reservation system?